Bristol-Myers Squibb (NYSE: BMY), with headquarters in New York City, is a global leader in the research and development of innovative treatments for cancer, hepatitis, HIV/AIDS, rheumatoid arthritis and other serious diseases.

Our key business is Biopharmaceuticals, with 2017 sales of US$20.8 billion and R&D investment of US$4.8 billion.

Bristol-Myers Squibb (Taiwan) Ltd., the Taiwan subsidiary, was setup by Bristol-Myers in August 1965, predating the 1989 merger with Squibb. In addition, service centers have been set up in Kaohsiung to a better serve the central and southern Taiwan markets.

BMS is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our employees around the world work together for patients – it drives everything we do. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.

We are committed to our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers.